Catalyst

Slingshot members are tracking this event:

AbbVie (ABBV) Releases Results from Three Pivotal Studies of Pan-Genotypic Chronic Hepatitis B Virus Infection Regimen Glecaprevir/Pibrentasvir to be Presented at The Liver Meeting in Boston, November 11 - 15

Source Link:
https://news.abbvie.com/news/eight-weeks-treatment-with-abbvies-investigational-pan-genotypic-regimen-glecaprevirpibrentasvir-gp-achieved-high-svr-rates-across-all-major-genotypes-chronic-hepatitis-c.htm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 15, 2016
Occurred Source:
https://news.abbvie.com/news/abbvies-investigational-pan-genotypic-regimen-glecaprevirpibrentasvir-gp-shows-high-svr-rates-in-chronic-hepatitis-c-patients-with-severe-chronic-kidney-disease.htm
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Edurance-1, Endurance-3, Surveyor-2, Glecaprevir, Pibrentasvir, Pivotal Studies, Pan-genotypic, Chronic Hepatitis B Virus Infection, Hbv, The Liver Meeting
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.